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OBJECTIVES This study aimed to investigate the impact of hydroxymethylglutaryl coenzyme A reductase
inhibitor (statin) therapy in patients with advanced heart failure (HF).
BACKGROUND Although statins are known to reduce mortality in coronary artery disease (CAD), the impact
of statin therapy in patients with HF has not been well studied. Both the potential risks and
benefits of statins in HF have been described.
METHODS We studied a cohort of 551 patients with systolic HF (left ventricular ejection fraction [EF]
40%) referred to a single university center for clinical management and/or transplant
evaluation. Survival without the necessity of urgent heart transplantation was determined.
RESULTS The patients’ mean age was 52  13 years; mean EF was 25  7%. Forty-five percent of the
cohort had CAD, and 45% were receiving statin therapy, including 73% and 22% of CAD
and non-CAD patients with HF, respectively. Patients receiving statins were significantly
older and more likely to be male, with higher rates of hypertension, diabetes, and smoking.
The EF and cholesterol levels were similar between treated and non-treated patients. Statin
use was associated with improved survival without the necessity of urgent transplantation in
both non-ischemic and ischemic HF patients (91% vs. 72%, p  0.001 and 81% vs. 63%, p
 0.001 at one-year follow-up, respectively). After risk adjustment for age, gender, CAD,
cholesterol, diabetes, medications, hemoglobin, creatinine, and New York Heart Association
functional class, statin therapy remained an independent predictor of improved survival
(hazard ratio 0.41 95% confidence interval 0.18 to 0.94).
CONCLUSIONS Statin therapy is associated with improved survival in patients with ischemic and non-
ischemic HF. Randomized trials are needed for confirmation of a therapeutic benefit. (J Am
Coll Cardiol 2004;43:642–8) © 2004 by the American College of Cardiology Foundationo
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pydroxymethylglutaryl coenzyme A reductase inhibitor
statin) therapy lowers morbidity and mortality in coronary
rtery disease (CAD) and other atherosclerotic vascular
isease, as evidenced by multiple large-scale clinical trials
1–4). Additional analyses of these trials have shown that
tatin therapy also reduces the risk of developing heart
ailure (HF) (5,6). A reduction in cardiovascular events with
tatin therapy has been demonstrated irrespective of baseline
ow-density lipoprotein (LDL) cholesterol (3). Therefore, it
s reasonable to hypothesize that statins would confer a
urvival benefit in patients with ischemic HF. Yet, the
mpact of statin therapy on HF progression has not been
reviously studied. The major clinical trials of statin therapy
ave generally excluded patients with symptomatic or severe
F (1–4).
Statins have therapeutic properties that are of potential
enefit to patients with HF of ischemic and non-ischemic
tiologies, irrespective of lipid levels. Statins may improve
ndothelial function, inhibit inflammatory cytokines, poten-
iate nitric oxide (NO) synthesis, restore impaired auto-
omic function, and reverse pathologic myocardial remod-
ling (7–12). On the other hand, concern has also been
aised about the potential adverse effects of statins in HF
13,14). Low cholesterol levels are associated with poor
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Manuscript received May 21, 2003; revised manuscript received July 2, 2003,uccepted July 28, 2003.utcomes in advanced HF (15,16), calling into question the
afety of lipid-lowering therapy in this population. Further-
ore, statins decrease levels of ubiquinone (coenzyme Q10),
hich may impact ventricular function and exercise toler-
nce in HF patients (13,14,17).
Statins are included as part of the medical regimen of only
portion of patients with CAD and HF. One-third of
schemic HF patients in one large population cohort (18)
nd between 11% to 45% of patients in large HF clinical
rials were treated with statins (14). Based on autopsy data,
p to 33% of the deaths in HF patients are related to acute
oronary syndromes (19). If statin therapy is safe and
ffective in reducing acute coronary events in patients with
F, millions of HF patients who would benefit from such
herapy are not currently being treated. Alternatively, if
tatins have adverse effects in HF, a large number of HF
atients are being exposed unnecessarily.
In light of the controversy surrounding statin use in
atients with HF, and without the results of ongoing
linical trials (14), we undertook the present study to
valuate the effect of statin therapy in a large, diverse cohort
f patients treated for advanced HF of multiple etiologies at
single university center.
ETHODS
atients. The study cohort consisted of 623 consecutive
atients referred to a specialized cardiomyopathy center at a
niversity hospital for clinical HF management and/or heart
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February 18, 2004:642–8 Statins and Survival in HFransplantation evaluation between January 2000 and De-
ember 2002. Patients were excluded from analysis if their
jection fraction (EF) was40% (n 60) or if baseline data
ere incomplete (n  12). The final patient cohort con-
isted of 551 patients. The Medical Institutional Review
oard approved the medical record review.
ata collection. All patients were followed in a compre-
ensive HF management program, as previously described
20). Detailed information on the patients’ medications and
oses was recorded at the initial visit and every follow-up
isit. Ejection fraction was determined by echocardiography
btained at the time of referral. Medications were deter-
ined by the patients’ individual HF physician and/or
eferring physician; medications were not assigned in a
andomized manner. Patients were considered to be receiv-
ng statin therapy if: 1) therapy was commenced before
eferral and continued throughout study period; or 2)
herapy was started within three months after the referral
ate and continued throughout the study period.
Laboratory testing, echocardiography, and right heart cath-
terization occurred within six weeks of the initial referral date.
emodynamic variables used in analyses were those obtained
fter optimal medical therapy had been instituted. Previous left
eart catheterization reports and angiographic films were
eviewed, or, if not done previously, left heart catheterization
as performed. Significant CAD was defined as any single
tenosis 70% of the cross-section lumen diameter of the
nvolved artery on angiography. Patients were classified as
aving HF due to non-ischemic cardiomyopathy if they had no
istory of myocardial infarction and cardiac catheterization was
ithout significant CAD.
nd points. All-cause mortality or urgent transplantation
status 1A) was the primary end point of the study. Status
A transplants were included in the primary end point,
ecause these patients are expected to live less than one
eek without a transplant and are dependent on intravenous
edication, ventricular assist device, or mechanical ventila-
ion, as previously described (21). Non-urgent transplants
status IB and II) were coded as a non-fatal end of follow-up
t the time of transplantation. Patients lost to follow-up
ere censored at the time they were last known to be alive
nd well.
tatistical analysis. Results are presented as the mean
alue  SD for continuous variables and as the percentage
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CAD  coronary artery disease
CI  confidence interval
EF  ejection fraction
eNOS  endothelial nitric oxide synthase
HF  heart failure
HR  hazard ratio
LDL  low-density lipoprotein
NO  nitric oxideff total patients for categorical variables. The independent
amples t test and chi-square test were used for comparison
f continuous and categorical variables, respectively. Sur-
ival curves were calculated by the Kaplan-Meier method.
nivariate and multivariate Cox regression analyses were
mployed to calculate the estimated hazard ratio (HR) with
5% confidence interval (CI), where appropriate. The Sta-
istical Package for Social Sciences (SPSS) for Windows,
ersion 11.0 (Chicago, Illinois) was used for all analyses. For
urvival free from urgent transplantation, the sample size
sed in our study would allow the detection of a 20%
ortality difference, with a power of 0.90 and an alpha level
f 0.05.
ESULTS
aseline characteristics of cohort. The age of the patients
anged from 18 to 84 years. The etiologies of HF included
schemic (45%), idiopathic (25%), valvular, alcoholic, and
eripartum. Forty-five percent of the cohort was treated
ith a statin, including 73% and 22% of ischemic and
on-ischemic HF patients, respectively. The characteristics
f the cohort are shown in Table 1. The prevalence of
ndividual statin and other lipid-lowering medications is
utlined in Table 2.
Patients receiving statin therapy were older and more
ikely to be male compared with patients not receiving statin
herapy. Patients receiving statins had higher rates of CAD,
ypertension, diabetes, and smoking. The lipid levels were
imilar between patients treated and those not treated with
tatins. The characteristics of the statin and no-statin
ohorts are detailed in Table 1.
elationship between statin therapy and survival.
uring the follow-up period, there were 73 deaths (32 due
o progressive HF, 23 sudden deaths, 2 due to myocardial
nfarction, and 16 unknown or other causes). There were
01 patients who received heart transplants (60 urgent and
1 non-urgent). Eighty-four patients (15%) were lost to
ollow-up. Actuarial survival free from urgent transplanta-
ion for the entire cohort was 75% at one year and 65% at
wo years.
Statin therapy was associated with significantly improved
urvival free from urgent transplantation. Survival without
rgent transplantation at one year was 84% in statin-treated
nd 70% in patients not treated with statins (HR 0.45, 95%
I 0.30 to 0.67). The two-year survival rates were also
ignificantly different; 79% in statin-treated patients and
1% in patients not treated with statins (HR 0.47, 95% CI
.32 to 0.69). When excluding urgent transplants as an end
oint, the one-year all-cause mortality rate was 11% in
atients receiving statins and 18% in those not receiving
tatins (HR 0.52, 95% CI 0.30 to 0.90) (Fig. 1). Table 3
utlines differences between survivors free from death or
rgent transplantation versus non-survivors at one year, as
ell as the univariate HR of death or urgent transplantationor each variable. Non-survivors at one year were similar to
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Statins and Survival in HF February 18, 2004:642–8urvivors in terms of age and gender. Non-survivors had
ignificantly higher pulmonary capillary wedge pressures,
ower left ventricular EF, lower total cholesterol levels, and
ower hemoglobin levels. Non-survivors were significantly
ess likely to have been treated with beta-blockers,
ngiotensin-converting enzyme (ACE) inhibitors, and st-
tins. When the cohort was subclassified according to those
live, dead, or undergoing urgent or non-urgent transplan-
ation at one-year follow-up, the rates of statin usage were
7%, 33%, 25%, and 63%, respectively.
Table 1. Characteristics of the Study Cohort: C
Statins and Patients Not Treated With Statins
Total
Cohort
Age (yrs) 52  13
Male (%) 76%
BMI (kg/m2) 27.5  6.2
NYHA class III (%) 44%
NYHA class IV (%) 33%
Ejection fraction (%) 25  7
Peak V˙O2 13.8  4.9
PCWP (mm Hg) 14  5
Baseline history
Ischemic etiology (%) 45%
Smoking† history (%) 73%
Hypertension (%) 54%
Diabetes (%) 24%
Baseline medications
Beta-blocker (%) 74%
ACEI or ARB (%) 89%
Spironolactone (%) 43%
Diuretics (%) 85%
Laboratory values
Total cholesterol (mg/dl) 170  57
LDL cholesterol (mg/dl) 100  40
HDL cholesterol (mg/dl) 38  15
Triglycerides (mg/dl) 166  155
Sodium (mmol/l) 136  5
Hemoglobin (g/dl) 13.2  1.9
Albumin (g/dl) 3.7  0.7
Creatinine (mg/dl) 1.5  1.7
*Comparison between statin and no-statin cohorts. †Smok
presented as the mean value  SD or percentage of patients
ACEI  angiotensin-converting enzyme inhibitor; ARB
high density lipoprotein; LDL  low-density lipoprotein;
capillary wedge pressure; V˙O2  oxygen consumption.
able 2. Prevalence of Lipid-Lowering Medication in the Study
ohort
one 281 (52.6%)
tatins
Atorvastatin 150 (28.1%)
Simvastatin 56 (10.6%)
Pravastatin 30 (5.6%)
Fluvastatin 7 (1.3%)
Lovastatin 5 (0.6%)
Cerivastatin 1 (0.2%)
ther
Gemfibrozil 3 (0.6%)
Niacin 2 (0.4%)
Fenofibrate 1 (0.2%)2Improved survival with statin therapy was observed in HF
atients with both ischemic and non-ischemic HF etiolo-
ies (Fig. 1). Survival free from urgent transplantation in
atients with ischemic HF at one year was 80% in statin-
reated patients and 57% in patients not treated with statins
HR 0.35, 95% CI 0.19 to 0.62). A significantly higher
ne-year survival free from urgent transplantation was also
emonstrated in patients with non-ischemic heart failure
90% vs. 71%; HR 0.27, 95% CI 0.11 to 0.69). There were
parison Between Patients Treated With
Statin
Treatment
No Statin
Treatment p Value*
57  11 48  13 0.0001
82% 70% 0.001
28.2  6.2 26.9  6.2 0.03
50% 39% 0.06
28% 37% 0.10
25  7 24  8 0.09
12.9  3.9 14.8  6.0 0.002
15  5 14  4 0.12
73% 22% 0.0001
80% 66% 0.006
64% 43% 0.0001
33% 16% 0.005
80% 69% 0.0001
92% 87% 0.08
39% 46% 0.12
89% 81% 0.006
173  52 168  61 0.34
103  42 98  37 0.20
38  14 38  16 0.89
170  119 163  198 0.68
137  4 136  5 0.004
13.2  1.8 13.2  2.0 0.51
3.7  0.6 3.6  0.9 0.10
1.5  1.3 1.6  1.9 0.33
fers to a previous or current history of smoking. Data are
otensin receptor blocker; BMI  body mass index; HDL 
A  New York Heart Association; PCWP  pulmonary
igure 1. Kaplan-Meier curves demonstrate one-year survival (%) without
he need for urgent heart transplantation in cohorts of non-ischemic (n om
ing re
.
 angi
NYH98) and ischemic (n  244) heart failure patients. Rx  therapy.
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February 18, 2004:642–8 Statins and Survival in HFimilar HRs for death from any cause, death from pump
ailure, and sudden death (Fig. 2).
Statin therapy was associated with a lower age- and
ender-adjusted risk of mortality or urgent transplantation
Table 4). After adjustment for demographic and HF
rognostic factors, including gender, age, medications, HF
tiology, total cholesterol level, New York Heart Associa-
ion functional class, hemoglobin, creatinine, and pulmo-
ary capillary wedge pressure, the risk of death or urgent
ransplantation remained significantly lower in the statin
ohort than in the no-statin cohort (Table 4). Furthermore,
he association between statin therapy and improved sur-
ival free from urgent transplantation persisted in clinically
ignificant subgroups of patients, including men and
omen, those with cholesterol above and below the median
alue (163 mg/dl), and those who did not receive heart
ransplants (Fig. 3). Baseline differences in beta-blocker
herapy use could not fully explain the lower mortality risk
een with statin therapy, because a similar benefit (HR 0.35,
5% CI 0.17 to 0.72) was seen when the analysis was
onfined to HF patients treated with optimal HF medical
herapy, including both ACE inhibitors and beta-blockers.
Table 3. Prediction of One-Year Mortality: Ch
of Urgent Transplantation Versus Non-Survivo
Survivors
(n  437)
N
Statin (%) 49
Age (yrs) 52  13
Male (%) 75
NYHA class IV (%) 22
Ejection fraction (%) 25  7
PCWP (mm Hg) 14  4
ACEI or ARB (%) 95
Beta-blocker (%) 80
Ischemic etiology (%) 49
Total cholesterol (mg/dl) 178  54
Hemoglobin (g/dl) 13.5  1.8
Creatinine (mg/dl) 1.5  1.8
*By the likelihood ratio test, Cox regression analysis. †Univ
hazard ratio of characteristic for categorical variables.
CI  confidence interval; NS  not significant; other ab
igure 2. One-year hazard ratios (HRs) and 95% confidence intervals
CIs) for death or urgent transplantation, death from any cause, progressive
eart failure death, and sudden death for patients receiving statins
ompared with those not receiving statins.ISCUSSION
lthough an abundance of clinical evidence supports statin
herapy in CAD and other atherosclerotic vascular disease
1–4), the effect of statins on clinical outcomes in patients
ith HF has not previously been reported. The present
tudy not only demonstrates the safety of statin use in
dvanced HF, but also shows a strong, independent associ-
tion between statin therapy and improved survival of
atients with both ischemic and non-ischemic HF. Despite
he greater abundance of poor prognostic factors in the
tatin cohort, including CAD, hypertension, smoking, dia-
etes, and low oxygen consumption on cardiopulmonary
xercise testing, statin use was associated with improved
utcomes. Furthermore, the improved outcomes were seen
egardless of cholesterol level, etiology of HF, or other HF
edications. Despite the association between low total
holesterol and impaired HF prognosis seen in this popu-
ation and reported elsewhere (15,16), patients receiving
tatins in this cohort had markedly better survival with less
eed for urgent heart transplantation. There are a variety of
otential mechanisms that could account for these observa-
ions, including statin effects that may be independent of
ipid lowering.
tatins and ischemic heart disease. The anti-athero-
hrombotic effects of statins clearly have potential for benefit in
atients with CAD-associated HF. Based on autopsy data,
teristics of Survivors Free From the Necessity
urvivors
113) p Value*
Hazard Ratio
(95% CI)†
29 0.0001 0.45 (0.30–0.67)
 13 NS —
77 NS —
76 0.0001 8.46 (4.81–14.88)
 7 0.03 0.97 (0.95–1.00)
 6 0.004 1.09 (1.03–1.16)
65 0.0001 0.13 (0.09–1.19)
47 0.0001 0.25 (0.17–0.37)
48 NS —
 58 0.0001 0.99 (0.98–0.99)
 2.0 0.0001 0.79 (0.71–0.87)
 0.8 NS —
hazard ratio per unit increase for continuous variables and
tions as in Table 1.
able 4. HR of Death or Urgent Transplant for Statin
reatment Versus No Statin Treatment: Univariate and
ultivariate Analyses
One-Year HR Two-Year HR
nivariate 0.45 (0.30–0.67) 0.47 (0.32–0.69)
ge- and gender-adjusted 0.44 (0.30–0.67) 0.47 (0.32–0.68)
ultivariate* 0.41 (0.18–0.94) 0.43 (0.20–0.94)
Multivariate analysis includes gender, age, angiotensin-converting enzyme inhibitor,
eta-blocker, heart failure etiology, total cholesterol level, New York Heart Associ-
tion functional class, hemoglobin, creatinine, and pulmonary capillary wedge
ressure after hemodynamically guided therapy.arac
rs
on-S
(n 
51
23
16
144
12.5
1.6
ariateHR  hazard ratio (95% confidence interval).
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Statins and Survival in HF February 18, 2004:642–80% of the sudden deaths and 26% of the non-sudden
ardiovascular deaths in patients with systolic HF were due to
cute coronary syndromes, the majority of which were not
iagnosed as acute coronary syndrome-related deaths until
utopsy (19). Statins promote atherosclerotic plaque stabiliza-
ion via inhibition of inflammatory macrophages, depletion of
he lipid core, and strengthening of the fibrous cap. Statins
ave clearly been demonstrated to reduce atherothrombotic
ardiovascular events in patients with clinically evident athero-
clerosis, even in the setting of baseline LDL cholesterol levels
f 100 mg/dl (3). Although patients with symptomatic HF
ave been excluded from these clinical trials, the mechanism
or atherosclerotic plaque rupture and the impact of statins on
laque stabilization could reasonably be expected to be similar
etween patients with and those without HF. Patients with
symptomatic left ventricular dysfunction (EF 25% to 40%) in
he Cholesterol And Recurrent Events (CARE) trial derived a
imilar pravastatin-related risk reduction as those patients
ithout significant left ventricular dysfunction (4).
The anti-ischemic effects of statins may extend beyond
laque stabilization. Experimental studies have consistently
emonstrated that statin treatment significantly reduces the
xtent of myocardial necrosis, preserves myocardial viability,
nd results in improved ventricular function in models of
yocardial ischemia/reperfusion injury. Decreases in ischemic
reas, repetitive stunning, and hibernation may lead to im-
rovement of myocardial function (22). Other anti-ischemic
haracteristics of statins include improvement in coronary
ndothelial function and possibly neoangiogenesis (23–25).
tatins and myocardial remodeling. Recently, statins have
een shown to have a direct impact on pathologic ventricular
emodeling and angiotensin II signaling—effects that would
ave therapeutic potential not only for ischemic HF but also
or HF in the absence of CAD. Rodent models of both
schemic and non-ischemic HF have shown statin therapy to
igure 3. Two-year rates of death or urgent transplantation in statin versus
o-statin cohorts. The benefit associated with statin therapy in the total
ohort was compared with subgroups of men and women, those with
holesterol above and below the median level (163 mg/dl), and a subgroup
xcluding patients who underwent elective or urgent transplantation. HR
hazard ratio with statin therapy (Rx); TC  total cholesterol.e associated with reverse remodeling and prolonged survival a10,11,26,27). In models of HF after myocardial infarction, the
athologic correlates of reverse remodeling included a reduc-
ion of matrix metalloproteinase activity in mice treated with
uvastatin and reduced expression of collagen in rats treated
ith cerivastatin (10,25). In a non-ischemic model of pressure
verload in rats with ascending aortic banding, statins pre-
ented left ventricular hypertrophy development via ras signal-
ng inhibition (26).
tatins and inflammation. Activation of inflammatory
ytokines, such as tumor necrosis factor-alpha and
nterleukin-6, has been associated with worse symptoms and
hortened survival in HF (28,29). Furthermore, cytokines
ay play a cytotoxic role in the pathophysiology of HF
rogression (30). Statins are now recognized as anti-
nflammatory agents that downregulate inflammatory cyto-
ines and C-reactive protein (7,9,31). Thus, statins may
lay a therapeutic role in HF via anti-inflammatory actions.
tatins and endothelial function/NO. Endothelial dys-
unction of the systemic vasculature characterized by im-
aired vasodilation and increased vasoconstriction, is seen in
F, whether ischemic or non-ischemic, and may contribute
o the exercise intolerance and end-organ dysfunction of
hronic HF. Furthermore, endothelial NO synthesis has
een shown to be diminished in HF (32). Statins improve
ndothelial function, an action likely mediated by enhance-
ent of endothelial NO synthase (eNOS) activity (24).
tatins have been demonstrated to activate the Akt pathway,
esulting in a rapid increase in NO bioavailability. The
ffects of statins on NO and endothelium have therapeutic
otential for chronic HF patients. Interestingly, in a recent
eport of an experimental model of infarct-induced HF,
ransgenic mice that overexpressed eNOS had better cardiac
utput, less pulmonary edema, and improved survival com-
ared with non-transgenic mice (33). Statin therapy may
ave beneficial effects in heart failure through improved
ndothelial function and enhanced bioavailability of NO.
tatins and neurohormonal systems. Sympathetic ner-
ous system activation, as indexed by plasma norepinephrine
evels, is associated with HF severity as well as increased HF
ortality (34). Recent animal studies suggest that statins
ave the ability to normalize sympatho-excitation in HF
12,35), suggesting another therapeutic action for statins in
F. In a recent report of rabbits with pacing-induced HF,
dministration of simvastatin decreased plasma norepineph-
ine levels and renal sympathetic nerve activity, as well as
ormalized baroreceptor responses (12).
Collectively, these studies provide plausible biologic
echanisms by which statins could exert cardiovascular
rotective effects in patients with advanced HF, thus reduc-
ng mortality and the need for urgent heart transplantations.
hese mechanisms are distinct from that of ACE inhibitors
nd beta-blockers, and the benefits of statin therapy would
e expected to be additive to existing HF therapy, as
bserved in this study. Although the results of this study
hould only be regarded as hypothesis-generating, the 14%
bsolute risk reduction in mortality associated with statin
t
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February 18, 2004:642–8 Statins and Survival in HFherapy in advanced HF at one year translates into seven
atients as the number needed to treat to save one life or
revent one urgent transplantation. Given the large number
f patients with HF and the magnitude of potential benefit
ith statin therapy, well-designed, prospective, randomized
linical trials are clearly needed. The Gruppo Italiano per lo
tudio della Sopravivenza nell’ Infarcto miocardico (GISSI)
nvestigators are conducting a clinical trial to assess the
mpact of statins on mortality in HF, and the RosUvastatiN
mpact on VEntricular Remodeling, LipidS, and Cyto-
inEs (UNIVERSE) study is investigating the effects of
tatins on remodeling (14).
tudy limitations. We acknowledge a number of limita-
ions of our study. Our analysis was retrospective in nature,
nd allocation of statin therapy was not randomized. The
uration and dosing of statins were not analyzed. Choles-
erol changes due to statin therapy were not recorded.
ropensity matching was not performed. Despite adjust-
ent for baseline differences and an abundance of poor
rognostic factors in the statin cohort, including older age,
AD, diabetes, and lower peak oxygen consumption, statin
reatment could still be a surrogate for other unmeasured
ariables that reflect a higher quality of care and more
ggressive treatment strategies. As such, a causal relation-
hip between the observed associations with statin use and
utcomes cannot be concluded. There was too infrequent
se of other non-statin lipid-lowering agents to determine
he relationship between the use of these agents and clinical
utcome.
onclusions. Our data suggest that statin therapy is safe in
F and furthermore is associated with improved outcomes.
tatin therapy may represent a novel treatment for patients
ith HF, irrespective of HF etiology, LDL cholesterol
evels, and the presence or absence of atherosclerosis. This
tudy calls attention to the potential role of statins as HF
herapy.
eprint requests and correspondence: Dr. Gregg C. Fonarow,
hmanson-UCLA Cardiomyopathy Center, Division of Cardiol-
gy, University of California at Los Angeles, 47-123 CHS, 10833
e Conte Avenue, Los Angeles, California 90095-1679. E-mail:
fonarow@mednet.ucla.edu.
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